Objective: The aim of this study was to analyze clinical characteristics of rocuronium as premedication for nonemergent intubation in infants.
Introduction
Premature newborns frequently require endotracheal intubation. Although several studies have shown adverse effects of awake intubations, [1] [2] [3] premedication with sedatives, analgesics or paralytics before this invasive procedure is not yet routine. 4 Successful intubations after fewer attempts are reported for chemically paralyzed newborns. 5 Improving intubation success rates is worthwhile, given data that reveal more than half of all intubation attempts by pediatric residents are unsuccessful, leading to multiple attempts by caregivers to properly place the endotracheal tube. 6 As of March 2010, the American Academy of Pediatrics endorses the use of premedication for nonemergent intubation; the clinical report by Kumar et al. 7 advocates for the administration of analgesic agents and states, 'vagolytic agents and rapid-onset muscle relaxants should be considered'.
Oei et al. 8 reported successful intubation of preterm and term infants by junior medical staff in fewer attempts after premedication with atropine, morphine and succinylcholine vs no premedication. Barrington and Byrne 9 reported similar success in neonates using atropine, fentanyl and succinylcholine. However, serious potential adverse effects of succinylcholine have shifted interest to nondepolarizing neuromuscular blocking agents as safer alternatives. Two recent investigations report using mivacurium to safely and effectively facilitate nonemergent intubations in neonates; 10, 11 unfortunately, this drug has since been discontinued. Rocuronium bromide (rocuronium) is another short-acting nondepolarizing agent that has been studied in older infant and pediatric populations, 12, 13 but has not, to our knowledge, been studied in neonates for nonemergent intubation in the neonatal ICU (NICU).
Intubations in our level-III NICU are performed by medical and neonatal nurse practitioner students, residents, neonatal nurse practitioners, fellows and attendings. Premedication for intubation is routine unless emergency conditions preclude intravenous placement for medication administration. Infants <36 weeks corrected gestational age (CGA) receive an intravenous dose of atropine followed by fentanyl; those X36 weeks receive atropine, fentanyl and rocuronium. We sought to compare intubation success rates for premature infants <36 weeks CGA premedicated with or without rocuronium in a randomized-controlled study. We also observed outcomes of all intubations occurring under rocuronium (by our NICU protocol or randomized trial) during the 12-month study period and report the clinical characteristics of rocuronium in our infant population.
Methods

Ethics
We obtained approval from our institutional review board for our randomized-controlled trial for infants <36 weeks CGA and our observational study for infants X36 weeks CGA. Informed consent was obtained before beginning these studies for the randomized trial; the consent requirement was waived for the observational study.
Methods by study population Randomized controlled trial: infants <36 weeks CGA. We compared intubation success rates between patients randomized to receive atropine and fentanyl with rocuronium (rocuronium group, RG) or without rocuronium (control group, CG) for nonemergent intubations during their NICU stay. For this randomized-controlled trial, all infants <35 6 7 weeks CGA were eligible for enrollment. Infants >36 weeks CGA already received rocuronium as part of premedication for intubation per our NICU protocol, and were therefore excluded from randomization and enrollment. Once a patient reached 36 weeks CGA, study intubations were complete. Future intubations then proceeded per established NICU protocol (atropine/fentanyl/muscle relaxant) regardless of group assignment. Infants with airway abnormalities that make intubation more difficult (for example, Pierre Robin sequence, cleft palate, pharyngeal perforation, subglottic stenosis, oral or neck masses) were excluded. Patients with contraindications for rocuronium (hypersensitivity to rocuronium or bromides and family history of myasthenia gravis) were excluded. Informed consents were obtained from parents before the need for intubation. A consented infant was randomized at the time of the first study intubation and remained in that group until the infant no longer met study criteria.
When intubation was required (as determined by the clinical team), an infant randomized to RG received atropine 0.02 mg kg À1 followed by fentanyl 2 mg kg À1 followed by rocuronium 0.5 mg kg
À1
. An infant in the CG received only atropine 0.02 mg kg À1 followed by fentanyl 2 mg kg À1 for premedication. An infant who was tachycardic (heart rate >180 beats per minute) did not receive atropine. All medications were given through intravenous route with normal saline flushes after each medication.
Information about intubation complications, results of each attempt and the intubator's level of experience were recorded on a worksheet by the intubator following each intubation. If successful intubation was not achieved by the third attempt by a lower-level trainee, a more senior caregiver (that is, neonatal nurse practitioner, fellow or attending) would continue the procedure. An intubation attempt was defined as insertion and removal of the laryngoscope blade. Successful intubation was confirmed by endtidal carbon dioxide detector, clinical signs and chest radiograph.
Onset of paralysis was timed by a stopwatch starting from completion of post-rocuronium flush infusion and ending with complete cessation of breathing and spontaneous movement at rest or in response to light tactile stimulation (of infant's foot or finger). The infant received positive pressure ventilation through bag mask during onset of paralysis and between intubation attempts. In general, if complete cessation of movement did not occur by 2 min, the clinician proceeded with intubation. Degree of paralysis was recorded by the clinician doing the intubation on a scale of 1 (no spontaneous movement or breathing) to 5 (vigorous spontaneous movement requiring physical restraint). Duration of muscle relaxation was judged clinically by the patient's nurse or respiratory therapist. The time between onset of paralysis to the return of any voluntary movement (breathing, spontaneous movement) was noted. A timer was set from time of paralysis to alert staff to assess movement at 10 min intervals for movement in response to light tactile stimulation if spontaneous movement was not noted.
Observational study: infants 36 weeks CGA and older. Intubations of all infants X36 weeks CGA who received rocuronium by NICU protocol were enrolled in an observational study. Infants received the atropine/fentanyl/rocuronium regimen previously described before intubation. Atropine was held if the infant was tachycardic. Data on intubations, intubator and effects of rocuronium as previously described were collected for this observational group.
Statistical methods
Facilitation of intubation: randomized-controlled trial. Characteristics of the patient and intubator in each intubation were presented in descriptive format. We used logistic regression analysis (SYSTAT version 11, Richmond, CA, USA) to examine how treatment group, chronological age, weight and intubator's level of training affected the success of intubation on first attempt. A P-value of <0.05 was considered significant.
Facilitation of intubation: rocuronium-facilitated intubations (randomized or per protocol).
Intubations under rocuronium that occurred as part of the randomized controlled trial (enrolled infants <36 weeks CGA) or as part of the observation of routine NICU protocol for infants X36 weeks CGA were combined for additional analysis. Outcomes of first intubation attempts and characteristics of the patient and intubator in each intubation were presented in descriptive format.
Effects of rocuronium
Onset and duration of paralytic effects of rocuronium were reported in descriptive statistics, including a box-and-whiskers plot (SPSS version 13, Chicago, IL, USA). The relationship of patient's weight, CGA and chronological age to onset and duration of rocuronium were examined using Spearman correlation coefficient (SYSTAT version 11). Adverse effects were presented in descriptive format.
Results
Facilitation of intubation
Randomized-controlled trial. Twenty-seven preterm infants were randomized and intubated per protocol; 11 patients were intubated on more than one occasion. After excluding one intubation from each group (protocol violations), details of 44 intubations (24 control, 20 experimental) were recorded. In the CG, for one intubation, two doses of fentanyl were given; data for this intubation were still included. One CG patient was intubated once under protocol, but due to a hypopharyngeal perforation during his next intubation, all subsequent intubations were excluded according to exclusion criteria. Atropine was omitted for tachycardia in one rocuronium and one CG intubation; atropine was initially omitted, then given between attempts for one rocuronium and two CG intubations.
The groups were similar in chronological and gestational age and weight at time of intubation (Table 1) . Respiratory failure was the most common indication for intubation in both groups (70% RG, 75% CG). Level of training among intubators ranged from senior medical students to neonatal attendings and was similar across both groups ( Table 1) . Level of experience (number of prior intubations, either attempted or successful) of the intubators was also similar in both groups for first attempt (data not shown). The most common reason for failure of first intubation attempt was the inability to place the tube through the vocal cords (20% in RG, 37.5% in CG) (Figure 1) .
Thirty-five percent (7) of intubations in RG vs 8% (2) of controls were successful on first attempt (P ¼ 0.057). When treatment group, chronological age, weight and intubator's level of training were examined by logistic regression analysis, premedication with rocuronium was the only significant variable (odds ratio ¼ 0.052, P ¼ 0.029) found to correlate with a successful intubation on first attempt.
Rocuronium-facilitated intubations (randomized or per protocol). Over the 12-month study period, 58 nonemergent intubations occurred after premedication with rocuronium. Data from one patient were excluded for deviating from protocol; after incomplete paralysis, that patient was given second dose of rocuronium. Patient characteristics for the remaining 57 rocuronium-assisted intubations are reported in Table 2 .
Respiratory failure was the most common reason for intubation (61%). Three (5.3%) intubations were performed without atropine; atropine was initially held, but then administered in two (3.5%) additional cases. Thirty-seven percent of all intubations using Figure 1 Reasons for intubation failure on first attempt (n ¼ 35).
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DM Feltman et al rocuronium were successful in the first attempt. Half (51%) of those intubating were interns (Table 2) . Thirty-five percent of those performing the first intubation attempt reported past experience of <5 intubations of infants <6 months; 23% reported over 20 prior intubations; 18% reported 10 to 20 prior intubations and 16%
reported no previous experience. Esophageal intubation was cited as the most common reason (33%) for failure of first intubation attempt, followed by inability to see vocal cords, oxygen desaturation and inability to see vocal cords with oxygen desaturation each accounting for 17% of failed first attempts.
Paralytic effects of rocuronium
On a Likert scale with 1 as no spontaneous movement or breathing and 5 as vigorous spontaneous movement requiring physical restraint, 46 (80.7%) of intubations were graded 1 and 11 (19.3%) graded 2. Timing data were missing for 2 of the 45 intubations reported as 1 (completely clinically paralyzed). The data for onset and duration of paralysis for the remaining 44 patients are reported in Table 2 and Figure 2 . Given the wide range of onset and duration times, nonparametric correlation analysis was performed. Patient's day of life, CGA and weight at time of intubation were analyzed with respect to onset and duration of paralysis. Overall, Spearman correlations were found to be weak.
Adverse effects of rocuronium
For the 57 intubations under rocuronium, tachycardia >180 beats per minute was reported in four cases (7%); the patients in these intubations had all received atropine. Bronchospasm was reported in one intubation, bradycardia in another. For intubations completed without rocuronium in the CG of the randomized control trial (24) , bradycardia was noted in 2 intubations (1 with atropine, 1 without), laryngospasm in 1 and bleeding in another.
Discussion
Common practices
Premedication for intubation with sedatives or paralytic agents in neonates is growing in support, though it is not yet widely practiced. In 1996, a survey by Ziegler and Todres 14 of 74 academic NICU centers who responded revealed only 3% routinely use sedatives, and 57% never used sedatives; 76 and 77% never used succinylcholine and nondepolarizing muscle relaxants, respectively. In 2000, approximately one-third of neonatologists surveyed by Hancock et al. 15 and Whyte et al. 16 reported providing premedication for intubation on a regular basis. Sixty-six percent of the time opioids were given, and 22% of the time paralytics were given. 16 In 2006, Sarkar et al. 17 surveyed 100 US neonatology program directors. In this survey, 34 of the 78 respondents reported using premedication for elective intubation; 25% use paralytics with sedation. 17 In adult and pediatric emergency room and intensive care units, 'rapid-sequence intubations' using neuromuscular-blocking agents are more common. 18, 19 Studies have shown increased rates of success 20, 21 and decreased rates of complications 22 in intubations performed after administration of neuromuscular paralysis in pediatric and adult patients.
Several prospective investigations in the neonatal population have reported similar favorable results. Three recent review articles summarize the outcomes of various premedication regimens for nonemergent intubation. [23] [24] [25] In addition to improving chances for successful intubation, paralytic agents are reported to attenuate adverse physiologic changes experienced during intubation attempts. Increased intracranial pressure, 2, 3, 26, 27 increased systolic blood pressure 28 and longer duration of hypoxemia 10, 29 have been reported in awake vs paralyzed neonatal intubations. The longterm consequences of these physiologic changes are not known.
Drug of choice
Roberts et al. 10 suggest that the reason premedication for intubation is not a widespread practice is because of lack of experience with these medications. Indeed, the drug best suited for the premedication of a neonate requiring intubation is not yet clear. Nondepolarizing agents have replaced succinylcholine for similar paralytic properties (quick onset, short duration) and safer side effect profiles. Roberts et al. 10 and Dempsey et al. 11 reported successful facilitation of intubations with mivacurium, only to have this drug out of production in May 2006, shortly after their studies were published. The American Academy of Pediatrics' clinical report encouraging premedication for nonemergent intubation acknowledges the need for further study to establish an 'ideal' combination of agents. 7 This is the first report to our knowledge that examines the efficacy and safety of rocuronium for the nonemergent endotracheal intubation in term and preterm infants in the NICU. Several studies provide information on the drug in older pediatric populations. Driessen et al. 12 and Rapp et al. 13 examined duration of muscle relaxation by observing train-of-four muscle twitches in infants 0 to 12 months using varying doses of rocuronium in conjunction with inhaled anesthetics. Both studies reported effects lasting 46 to 100 min on average; in general, the duration of action was shorter after lower doses (0.3 and 0.45 mg kg À1 ) vs 0.6 mg kg À1 . Using the rocuronium dose of 0.5 mg kg À1 in our study, we found the duration of rocuronium to be much shorter (judged by gross motor movements); this difference is likely due to prolongation of duration of rocuronium by inhaled anesthetic agents in the aforementioned studies. 13 Prospective studies by Roberts et al. 10 and Dempsey et al.
11
showed successful facilitation of endotracheal intubation in neonatal populations similar to ours using mivacurium. Roberts et al. 10 showed higher success rates for intubations by the second attempt, shorter duration of intubation procedure and decreased periods of desaturations. Dempsey et al. 11 showed facilitation of successful intubation by trainees with no previous experience. We found a significant increase in successful intubations on first attempt, regardless of other variables that may affect intubation, such as weight, gestational age, chronological age and the intubator's level of training.
In our patients who received rocuronium, the onset of paralysis was judged clinically as complete cessation of breathing or movement. Eighty percent of patients were scored 'completely paralyzed' on a Likert scale. For these 45 patients, there was a wide variation of time to onset of paralysis (14 to 178 s; mean±s.d., 67.0 ± 43.3 s). These times are similar to the onset times reported by Dempsey et al. 11 for mivacurium (range 30 to 240 s, mean 94 ± 51); Roberts et al. 10 did not publish this information. Duration of paralysis (judged clinically as return of breathing or any movement) for our patients receiving rocuronium ranged from 1 to 60 min (mean ± s.d., 16.2 ± 13.6 min). Studies of mivacurium for intubation of neonates reported shorter duration of paralysisFDempsey et al. 11 reported range of 8 to 30 min (mean 15.6 min); Roberts et al. 10 reported 5 to 22 min (mean 11 min, 26 s).
Rocuronium appears to be a suitable paralytic agent for the facilitation of nonemergent intubations. As a nondepolarizing neuromuscular blocker, it has a safer side effect profile than succinylcholine. Rocuronium has similar onset and duration of action to mivacurium, which has been shown effective in facilitating intubations, but is no longer available. Although work has been done in older pediatric populations, [30] [31] [32] [33] further studies are needed to better understand the pharmacokinetics of rocuronium in the neonatal ICU population. Pain upon intravenous infusion has been reported, though premedication with analgesics have been studied, and fentanyl was noted to decrease pain responses in one study. 34 Optimal dosing to maximize the number of completely paralyzed patients, provide quick onset of action, and minimize duration of paralysis in the neonatal and infant populations requires further investigation.
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